Fibrinolysis for intermediate-risk pulmonary embolism
- PMID: 25099593
- PMCID: PMC4375437
- DOI: 10.1056/NEJMc1406283
Fibrinolysis for intermediate-risk pulmonary embolism
Conflict of interest statement
No potential conflict of interest relevant to this letter was reported.
Comment in
-
Fibrinolysis for intermediate-risk pulmonary embolism.N Engl J Med. 2014 Aug 7;371(6):581-2. doi: 10.1056/NEJMc1406283. N Engl J Med. 2014. PMID: 25099590 No abstract available.
Comment on
-
Fibrinolysis for patients with intermediate-risk pulmonary embolism.N Engl J Med. 2014 Apr 10;370(15):1402-11. doi: 10.1056/NEJMoa1302097. N Engl J Med. 2014. PMID: 24716681 Clinical Trial.
References
-
- Genét GF, Ostrowski SR, Sørensen AM, Johansson PI. Detection of tPA-induced hyperfibrinolysis in whole blood by RapidTEG, KaolinTEG, and functional fibrinogenTEG in healthy individuals. Clin Appl Thromb Hemost. 2012;18:638–44. - PubMed
-
- Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res. 2005;66:276–85. - PubMed
-
- Angleton P, Chandler WL, Schmer G. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1) Circulation. 1989;79:101–6. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical